Author:
Nagengast Wouter B.,Munnink Thijs H. Oude,Dijkers Eli C. F.,Hospers Geke A. P.,Brouwers Adrienne H.,Schröder Carolien P.,Hooge Marjolijn Lub-de,de Vries Elisabeth G. E.
Reference85 articles.
1. Hait WN, Yang JM (2005) Clinical management of recurrent breast cancer: development of multidrug resistance (MDR) and strategies to circumvent it. Semin Oncol 32:S16–S21
2. Pusztai L, Wagner P, Ibrahim N et al (2005) Phase II study of tariquidar, a selective P-glycoprotein inhibitor, in patients with chemotherapy-resistant, advanced breast carcinoma. Cancer 104:682–691
3. Hendrikse NH, Franssen EJ, van der Graaf WT, Vaalburg W, de Vries EG (1999) Visualization of multidrug resistance in vivo. Eur J Nucl Med 26:283–293
4. Kostakoglu L, Elahi N, Kiratli P et al (1997) Clinical validation of the influence of P-glycoprotein on technetium-99m-sestamibi uptake in malignant tumors. J Nucl Med 38:1003–1008
5. Ciarmiello A, Del Vecchio S, Silvestro P et al (1998) Tumor clearance of technetium 99m-sestamibi as a predictor of response to neoadjuvant chemotherapy for locally advanced breast cancer. J Clin Oncol 16:1677–1683
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献